DOW JONES23,719.37+285.80 1.22%
S&P 5002,789.82+39.84 1.45%
NASDAQ8,153.58+62.67 0.77%

H.C. Wainwright Reiterates Buy on Fulcrum Therapeutics, Raises Price Target to $28

H.C. Wainwright analyst Andrew Fein reiterates Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and raises the price target from $21 to $28.

Benzinga · 03/06/2020 13:11

H.C. Wainwright analyst Andrew Fein reiterates Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and raises the price target from $21 to $28.